Download PDF
CC BY-NC-ND 4.0 · Indian Journal of Neurosurgery 2017; 06(03): 176-183
DOI: 10.1055/s-0037-1598091
Original Article
Thieme Medical and Scientific Publishers Private Ltd.

Evaluation of Factors Affecting Outcome in Growth Hormone–Secreting Pituitary Adenomas

Amit Padwal
1   Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bengaluru, India
,
Jagath Lal Gangadharan
1   Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bengaluru, India
,
Dwarakanath Srinivas
1   Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bengaluru, India
,
Sampath Somanna
1   Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bengaluru, India
› Author Affiliations
Further Information

Publication History

21 July 2016

18 October 2016

Publication Date:
22 September 2017 (online)

Also available at
   Permissions and Reprints

Abstract

Introduction Management of functioning pituitary adenomas is challenging as they can present with features of an intracranial mass, systemic effects, or a combination of both. In this series, one of the largest in available literature from our country, we have analyzed our experience with surgical management of growth hormone (GH)-secreting pituitary adenomas and factors influencing their hormonal remission.

Materials and Methods The data of all functional pituitary adenomas operated at our institute from January 2002 to December 2011 were obtained from the case files of these patients. This was studied for various clinical-radiologic features, management stratagems, and clinical and hormonal outcomes.

Results Ninety-three patients of GH-secreting pituitary adenomas with a mean age of 32.7 years were included in the study. Fifty-three (57%) patients had headache at presentation; 46 (49%) had visual complaints, whereas menstrual irregularity was seen in majority of females. Mean GH level was 52.05 ng/mL. Fifty (53%) patients had invasive adenoma; 32 had cavernous sinus extension. Among 80 patients with hormonal follow-up, 43 (53.75%) achieved remission of GH level < 5 ng/mL.

Conclusion In this series, one of the largest of its kind, the main factors influencing unfavorable outcome include macroadenomas, invasiveness, high basal GH > 45 ng/mL levels, and mixed adenomas.

Keywords

pituitary adenomas - invasive adenoma - growth hormone–secreting adenomas - acromegaly
 

  • References

  • 1 Esposito V, Santoro A, Minniti G. , et al. Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients. Neurol Sci 2004; 25 (05) 251-256
    CrossrefPubMedGoogle Scholar
  • 2 Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2 (01) 29-41
    CrossrefPubMedGoogle Scholar
  • 3 John A, Kamal T, Edward R. Pituitary tumors-functioning and Nonfunctioning. In: Richard WH. , ed. Youmans Neurological Surgery. 6th ed, Vol 2. Philadelphia, PA: Elsevier Saunders; 2011. :chap 34
    Google Scholar
  • 4 Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21 (03) 669-692
    CrossrefPubMedGoogle Scholar
  • 5 Sheaves R, Jenkins P, Blackburn P. , et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996; 45 (04) 407-413
    CrossrefPubMedGoogle Scholar
  • 6 Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 1988; 68 (06) 854-867
    CrossrefPubMedGoogle Scholar
  • 7 Losa M, Oeckler R, Schopohl J, Müller OA, Alba-Lopez J, von Werder K. Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurement in acromegaly. J Neurosurg 1989; 70 (04) 561-567
    CrossrefPubMedGoogle Scholar
  • 8 Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg 1993; 78 (02) 205-215
    CrossrefPubMedGoogle Scholar
  • 9 Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992; 21 (03) 693-712
    CrossrefPubMedGoogle Scholar
  • 10 Laws Jr ER, Thapar K. Recurrent pituitary adenomas. In: Landolt AM, Vance ML, Reilly PL. , eds. Pituitary Adenomas. Edinburgh, UK: Churchill Livingstone; 1996: 385-94
    Google Scholar
  • 11 Möller-Goede DL, Brändle M, Landau K, Bernays RL, Schmid C. Pituitary apoplexy: re-evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome. Eur J Endocrinol 2011; 164 (01) 37-43
    CrossrefPubMedGoogle Scholar
  • 12 Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 2003; 10 (04) 611-619
    CrossrefPubMedGoogle Scholar
  • 13 Kreutzer J, Vance ML, Lopes MB, Laws Jr ER. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001; 86 (09) 4072-4077
    CrossrefPubMedGoogle Scholar
  • 14 Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998; 83 (10) 3411-3418
    CrossrefPubMedGoogle Scholar
  • 15 Swearingen B, Barker II FG, Katznelson L. , et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83 (10) 3419-3426
    PubMedGoogle Scholar
  • 16 Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998; 89 (03) 353-358
    CrossrefPubMedGoogle Scholar